Total
0
Shares

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness (PSYC) will be participating in the upcoming H.C. Wainwright's Psychiatry and Beyond Virtual Conference on June 17
  • Conference information, registration and a link to the webcast are available on H.C. Wainwright's Events website
  • Psyched Wellness Ltd. is a Canadian-based health supplements company
  • Psyched Wellness Inc. (PSYC) opened trading at C$0.30 per share

Psyched Wellness (PSYC) will be participating in the upcoming H.C. Wainwright's Psychiatry and Beyond Virtual Conference on Thursday, June 17 2021.

For more information regarding these investor conferences, please visit the sponsor's conference website above.

To schedule a one-on-one meeting with management please reach out to your conference representative or the company's investor contact.

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

Psyched Wellness is developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: the promotion of stress relief, relaxation and assist with restful sleeping.

Psyched Wellness Inc. (PSYC) opened trading at C$0.30 per share.

More From The Market Herald

" Optimi Health (CSE:OPTI) engages U.S. based law firm for patent support

Optimi Health Corp. (OPTI) is working with Thomas Finetti, partner at Charney IP Law, to oversee ongoing patent activities.

" Entheon Biomedical (CSE:ENBI) subsidiary partners with 3W Wellness

Entheon Biomedical (ENBI) subsidiary, HaluGen Life Sciences, has partnered with 3W Wellness to drive brand awareness.

" Red Light Holland (CSE:TRIP) partnering with fresh and dried mushroom producers

Red Light Holland (TRIP) has entered a non-binding letter of intent to acquire a 51-per-cent stake in Acadian Exotic Mushrooms Ltd.

" Core One (CSE:COOL) subsidiary developing psychedelic drug formulation AKO001

Core One Labs (COOL) subsidiary Akome Biotech Ltd. is developing a psychedelic drug formulation to reduce neurological damage resulting from ischemic strokes.